期刊名称：CLINICAL CANCER RESEARCH
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Clinical Cancer Research (ISSN 1078-0432) is published twice monthly, one volume/year, by the American Association for Cancer Research, Inc. (AACR), 615 Chestnut Street, 17th Floor, Philadelphia, PA 19106-4404. Telephone: (215) 440-9300; Fax (215) 440-9354; E-mail: pubs@aacr.org.
Scope: Clinical Cancer Research publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome, and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients. All submissions undergo peer review.
Clinical Cancer Research is abstracted or indexed in Chemical Abstracts, Current Contents/CM? CancerLit, Index Medicus, and MEDLINE. The journal is printed on acid-free paper in the U.S.A.
Address editorial correspondence to: John Mendelsohn, M.D., Editor-in-Chief, c/o Department of Educational Publishing Services--227, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030. Telephone: (713) 792-6015; Fax: (713) 792-6016. See Instructions for Authors for manuscript submission information.
Subscriptions: For subscription information, click here.
Back Issues and Single Copy Sales: Copies of back stock of the journal Clinical Cancer Research may be ordered from AACR Subscription Office, P.O. Box 11806, Birmingham, AL 35202. Telephone: (800) 633-4931; (205) 995-1567 outside U.S. Fax: (205) 995-1588. As long as supplies permit, single copies of Clinical Cancer Research will be sold at $25 per copy, plus $3 shipping for orders outside the U.S.
Advertising representative: M. J. Mrvica Associates, Inc., 2 West Taunton Avenue, Berlin, NJ 08009. Telephone: (856) 768-9360. Fax: (856) 753-0064. Advertisement insertion orders and copy must be received 1 month prior to the date of the issue in which the advertisement is to be published. The journal is mailed by approximately the first day of the month of issue.
Instructions to Authors
Scope
Clinical Cancer Research, a journal of the American Association for Cancer Research, publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients.
Specific areas of interest include clinical and translational research in: molecular pharmacology and chemotherapy; drug sensitivity and resistance; tumor immunology and immunotherapy; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genes; pathology, markers, and prognostic indicators; growth factors, cytokines, and signal transduction; bone marrow transplantation; gene therapy; cancer endocrinology; cell adhesion, invasion, and metastasis; prevention of primary and recurrent cancer; differentiation and cell death; clinical genetics; and detection of minimal disease.
Editorial Policy
When a manuscript is received for consideration, the Editors assume that no similar paper has been or will be submitted for publication elsewhere. Further, it is understood that all authors listed on a manuscript have agreed to its submission. The signature of the corresponding author on the letter of submission signifies that these conditions have been fulfilled.
Journal policy requires that authors, reviewers, Associate Editors, and Senior Editors reveal in a letter to the Editor-in-Chief any relationships that they have that could be construed as causing a conflict of interest with regard to a manuscript under review. The letter should include a statement of any financial relationships with commercial companies involved with a product under study.
Upon acceptance, authors must transfer copyright to the American Association for Cancer Research, Inc., the copyright owner of the journal, prior to publication. Once an article is accepted for publication in Clinical Cancer Research, the information therein is embargoed from reporting by the media until the mail date of the issue in which the article appears.
The Editors endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving humans will have been performed in accordance with these principles. To obtain a copy of the Helsinki Declaration, please contact the World Medical Association, 28, Ave. des Alpes, F-01210, Ferney-Voltaire, France. For animal experimentation reported in the journal, it is expected that investigators will have observed the Interdisciplinary Principles and Guidelines for the Use of Animals in Research, Testing, and Education issued by the New York Academy of Sciences' Ad Hoc Committee on Animal Research, a copy of which is available for $5.00 from the Marketing Department, New York Academy of Sciences, 2 East 63rd Street, New York, NY 10021-7289. All human and animal studies must have been approved by the investigator's Institutional Review Board.
Review Process
The review process is conducted as rapidly as possible. Each submitted manuscript is reviewed by at least two experts in the field of investigation. If the authors are invited to submit a revised manuscript for an expedited further review, the revised version must be submitted within three months.
Publication Fees
A per-page charge for each published page ($75 per page for the first 6 published pages; $115 per page for each additional published page) will be levied on all manuscripts accepted for publication. It is understood at the time of submission that the author(s) agree to pay this charge in the event of publication. Under exceptional circumstances, when no grant or other source of support exists, the author(s) may apply to Kathleen Case, Publisher, AACR Publications Department (see below for address) at the time of acceptance for a waiver of the page charges. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges.
Procedures for Submission
Submit papers directly to the Deputy Editor or to one of the seven Senior Editors, each of whom is responsible for a particular area of research. The Deputy Editor and the Senior Editors will conduct the review process with the expert assistance of the journal's Associate Editors, will correspond with authors about their manuscripts, and will make editorial decisions regarding publication. Papers within the subject areas covered by the Editor-in-Chief, as well as manuscripts that do not pertain to any of the research areas listed, should be submitted to Dr. Mendelsohn. Research areas, mailing addresses, and telephone and fax numbers for the Editor-in-Chief, Deputy Editor, and Senior Editors can be found at the end of these Instructions.
Submit four original sets (not photocopies) of figures along with four copies of the manuscript. If a manuscript is closely related to papers that are in press or have been submitted elsewhere, please provide copies of those papers with your submission. For both original and revised submissions, we cannot guarantee that manuscripts and illustrations will be returned to the author.
The letter of submission can suggest the Associate Editors who might serve as reviewers of the manuscript. In addition, we invite authors to provide the names, addresses, and telephone/fax numbers of other potential reviewers who are not current or recent collaborators or advisors in the area under investigation.
Advances in Brief will be reserved for concise, definitive reports of novel observations and discoveries that have unusual importance. A request for consideration for Advances in Brief should be included in the letter of submission. A Minireview is a brief analysis (typically 3-4 printed pages) of a focused, timely research topic, aimed at a multidisciplinary audience. Minireviews and Controversies in Clinical Cancer Research that are submitted or solicited will undergo editorial review. The Editors welcome Letters to the Editor, which will be published if they are determined to be appropriate.
Format
Manuscripts must be written succinctly in clear, grammatical English. Define abbreviations in an inclusive footnote to the text. Double-space on 8 ?x 11-inch paper. Dot-matrix printing is not acceptable. The format is as follows:
1. Title page, including title, authors and their institutions, research support, and address plus telephone/fax numbers of the corresponding author;
2. A running title of fewer than 50 characters;
3. Three to five key words that do not appear in the title;
4. Abstract, of not more than 250 words, organized in paragraphs presenting the following four topics: Purpose, Experimental Design, Results, Conclusions;
5. Text arranged in this order: Introduction, Materials (or Patients) and Methods, Results, Discussion, Acknowledgments, References;
6. Footnotes, on a page separate from the text. Designate footnotes consecutively with superscript Arabic numerals;
7. Tables, one per page and separate from the text, with descriptive titles (no legends and no page numbers) that make the data understandable without reference to the text;
8. Figure legends, on numbered pages separate from the figures, with descriptive titles and explanations to make the data understandable without reference to the text. Define all symbols and include staining for halftones where applicable;
9. Figures.
References
Include only those articles that have been published or are in press. Unpublished data or personal communications must be cited as footnotes to the text. Personal communications should be substantiated by a letter of permission. Number references in the order of their first mention in the text. Cite only the number assigned to the reference. References must be double-spaced and include at least 10 authors before "et al."
SAMPLE REFERENCES:
1. Shaffer, D. W., Smith, L. S., Burris, H. A., Clark, G. M., Eckardt, J. R., Fields, S. M., Weiss, G. R., Rinaldi, D. A., Bowen, K. J., Kuhn, J. G., and Von Hoff, D. D. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies. Cancer Res., 53: 5929-5933, 1993.
2. Dimaggio, J. J., Scheinberg, D. A., and Houghton, A. N. Monoclonal antibody therapy of cancer. In: H. M. Pinedo, B. A. Chabner, and D. L. Longo (eds.), Cancer Chemotherapy and Biological Response Modifiers Annual, Vol. 11, pp. 177-203. Amsterdam: Elsevier Science Publishers B. V., 1990.
Figures
Provide four original sets of figures (whether line-cut drawings or halftones), and an electronic version on floppy disk, zip disk, or CD-ROM. Each sorted set should be in a separate labeled envelope, for distribution to reviewers. A typed label placed on the reverse side of each figure should contain the first author's name, figure number, and an arrow indicating top of figure. Letters and numbers on figures should not be smaller than 6-point or larger than 12-point type.
Authors are encouraged to submit color figures. The expense of reproducing color photographs must be offset partially by the author. The cost of color reproduction charged to authors in 2003 is $750 per color figure. Authors should include a statement that they are aware of and approve this cost.
Proofs
Page proofs must be returned to the office of the American Association for Cancer Research within 24 hours of receipt. Return proofs by overnight mail. Proofs not received by the deadline will be either rescheduled for a future issue, or published without the authors' corrections. Accepted manuscripts are regarded as final copy and should not be altered substantially in proof. Extensive alterations could cause publication delays, and authors will be charged for extensive alterations in proof.
Typesetting Manuscripts from Disks and CD-ROM
Clinical Cancer Research requires all manuscripts and figures to be submitted electronically (floppy disk, zip disk, CD-ROM) to expedite production of accepted manuscripts. If your article is accepted for publication, you will receive instructions regarding electronic submission. It is the author's responsibility to ensure that the material presented electronically matches the final accepted version of the manuscript.
"Disk Submission Form" in PDF format
Download Adobe Acrobat Reader 4.0
Research Areas of the Editor-in-Chief, Deputy Editor, and Senior Editors
John Mendelsohn, M.D., Editor-in-Chief
Department of Educational Publishing Services--227
The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Boulevard
Houston, TX 77030
Phone: (713) 792-6015; Fax: (713) 792-6016
E-mail: jmendelsohn@mdanderson.org
Growth factors, hormones, cell growth;
radiation therapy, surgery, and subspecialty investigation
Waun Ki Hong, M.D., Deputy Editor
Department of Thoracic/Head & Neck Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Box 432
1515 Holcombe Boulevard
Houston, TX 77030
Phone: (713) 792-6363; Fax: (713) 796-8655
E-mail: whong@mdanderson.org
Clinical trials targeted at specific malignancies, chemoprevention
William N. Hait, M.D., Ph.D., Co-Deputy Editor
The Cancer Institute of New Jersey
The UMDNJ/Robert Wood Johnson Medical School
195 Little Albany St., P.O. Box 2681
New Brunswick, NY 08903-2681
Phone: (732) 235-8373; Fax: (732) 235-8374
E-mail: haitwn@umdnj.edu
Special features, molecular pharmacology, clinical trials
Bruce A. Chabner, M.D.
Department of Hematology/Oncology
Massachusetts General Hospital
Cox Building, Room 640
100 Blossom Street
Boston, MA 02114
Phone: (617) 724-3200; Fax (617) 724-3166
E-mail: chabner.bruce@mgh.harvard.edu
Editorial Board
John D. Minna
Bruce Minsky
Malcolm S. Mitchell
Richard A. Morgan
Monica Morrow
Michael A. Morse
Hasan Mukhtar
Carolyn Y. Muller
James L. Mulshine
William G. Nelson
Larry Norton
Makoto Ogawa
Michael O'Reilly
Richard J. O'Reilly
Robert F. Ozols
Klaus Pantel
Jae-Gahb Park
Harvey Pass
Ira Pastan
Richard Pazdur
Roman Perez-Soler
David G. Pfister
Kenneth J. Pienta
|
